The way brands engage healthcare providers (HCPs) is undergoing a seismic shift in today’s digital-first healthcare ecosystem. The sales rep model is fading.
The US FDA has approved a fourth product via its new National Priority Voucher Programme -- a 7.2 mg dose of Novo Nordisk's weight loss drug Wegovy (semaglutide), to be marketed as Wegovy HD.
